[go: up one dir, main page]

DE69600399D1 - Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung - Google Patents

Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung

Info

Publication number
DE69600399D1
DE69600399D1 DE69600399T DE69600399T DE69600399D1 DE 69600399 D1 DE69600399 D1 DE 69600399D1 DE 69600399 T DE69600399 T DE 69600399T DE 69600399 T DE69600399 T DE 69600399T DE 69600399 D1 DE69600399 D1 DE 69600399D1
Authority
DE
Germany
Prior art keywords
treatment
cgrp antagonist
skin erythema
received
neurogenic origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69600399T
Other languages
English (en)
Other versions
DE69600399T3 (de
DE69600399T2 (de
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69600399(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of DE69600399D1 publication Critical patent/DE69600399D1/de
Publication of DE69600399T2 publication Critical patent/DE69600399T2/de
Publication of DE69600399T3 publication Critical patent/DE69600399T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69600399T 1995-03-28 1996-03-04 Verwendung eines Antagonisten von CGRP für die Behandlung von Hautrötungen neurogenen Ursprungs und erhaltene Zusammensetzung Expired - Lifetime DE69600399T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503628 1995-03-28
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (3)

Publication Number Publication Date
DE69600399D1 true DE69600399D1 (de) 1998-08-13
DE69600399T2 DE69600399T2 (de) 1998-10-29
DE69600399T3 DE69600399T3 (de) 2005-07-14

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69600399T Expired - Lifetime DE69600399T3 (de) 1995-03-28 1996-03-04 Verwendung eines Antagonisten von CGRP für die Behandlung von Hautrötungen neurogenen Ursprungs und erhaltene Zusammensetzung

Country Status (15)

Country Link
US (2) US5932215A (de)
EP (1) EP0734729B2 (de)
JP (1) JPH08268874A (de)
AR (1) AR002974A1 (de)
AT (1) ATE168011T1 (de)
BR (1) BR9601478A (de)
CA (1) CA2172777C (de)
DE (1) DE69600399T3 (de)
DK (1) DK0734729T4 (de)
ES (1) ES2121461T5 (de)
FR (1) FR2732221B1 (de)
HU (1) HUP9600765A3 (de)
MX (1) MX9601150A (de)
PL (1) PL313515A1 (de)
RU (1) RU2152798C1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
EP2241560A3 (de) * 2001-08-24 2014-07-09 Matthias Rath Ascorbic säure Derivaten, Verfahren zum Herstellung und pharmaceutisches Verwendung deren
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
NZ538615A (en) 2002-08-12 2008-03-28 Actavis Group Hf Use of CGRP antagonist compounds for treatment of psoriasis
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1957106B2 (de) 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Antagonisten-antikörper gegen calcitonin-gen-related-peptid und verfahren damit
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
CA2727710C (en) * 2008-06-11 2016-11-01 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2726726A1 (en) 2008-09-10 2010-03-18 Thrubit B.V. Ibuprofen for topical administration
EP2207536A1 (de) 2008-09-22 2010-07-21 BioChemics, Inc. Ausgabe eines transdermalen wirkstoffs mit einem osmolyt und einem vasoaktiven mittel
EP2352543B1 (de) * 2008-12-04 2019-04-03 BioChemics, Inc. Verfahren und zusammensetzungen zur entfernung von tätowierungen
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
KR20130018739A (ko) 2010-03-03 2013-02-25 네오큐티스 에스아 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법
JP5747391B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 紅斑の安全かつ有効な治療のための改善された方法および組成物
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (de) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DK0751789T3 (da) * 1994-03-21 2003-09-08 Thomsen John Brown Gel til behandling af hudsygdomme og til desinfektion af huden
EP0704210B1 (de) * 1994-09-30 2002-12-04 L'oreal Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
JPH08268874A (ja) 1996-10-15
EP0734729B1 (de) 1998-07-08
HUP9600765A3 (en) 1998-04-28
US5932215A (en) 1999-08-03
DK0734729T4 (da) 2004-10-25
ES2121461T3 (es) 1998-11-16
DE69600399T3 (de) 2005-07-14
ES2121461T5 (es) 2005-05-01
FR2732221A1 (fr) 1996-10-04
MX9601150A (es) 1997-02-28
EP0734729B2 (de) 2004-09-29
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
EP0734729A1 (de) 1996-10-02
CA2172777C (fr) 2007-07-24
PL313515A1 (en) 1996-09-30
DK0734729T3 (da) 1999-04-19
BR9601478A (pt) 1998-06-02
FR2732221B1 (fr) 1997-04-25
HUP9600765A2 (en) 1997-06-30
CA2172777A1 (fr) 1996-09-29
ATE168011T1 (de) 1998-07-15
DE69600399T2 (de) 1998-10-29
AR002974A1 (es) 1998-05-27
HU9600765D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
DE69600399D1 (de) Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
ATE278400T1 (de) Zusammensetzungen für die verwendung bei der behandlung und prävention von hyperurikämie
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
ATE229940T1 (de) 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren
DE69823459D1 (de) Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen
DE69600048D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE69941266D1 (de) Batchweise behandlung von job-signalen in einem multiverarbeitungssystem
DE69719603D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69222258D1 (de) Einrichtung und Verfahren für die Behandlung von Aussenwänden
DE69620270D1 (de) Backfett und dessen Verwendung
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69501493D1 (de) Entfernung von Feuchtigkeit und Passivierung von Oberflächen
IT1284499B1 (it) Apparecchiatura di monitoraggio dell'attivita' tettonica
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
ATE318602T1 (de) Kombination aus einem alpha-1-adrenorezeptor antagonisten und einem cgm pdev hemmer zur behandlung von impotenz
FR2733909B1 (fr) Compositions cosmetiques pour la photoprotection de la peau et/ou des cheveux a base d'un melange synergique de filtres et utilisations
IT1277461B1 (it) Procedimento e dispositivo per il trattamento di materiali
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings